Theralase Financial Statements From 2010 to 2025

Stocks . Canada . 
Stock . Theralase Technologies
TLT Stock  CAD 0.28  0.01  3.70%   
Theralase Technologies financial statements provide useful quarterly and yearly information to potential Theralase Technologies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Theralase Technologies financial statements helps investors assess Theralase Technologies' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Theralase Technologies' valuation are summarized below:
Gross Profit
628.2 K
Market Capitalization
66.3 M
Enterprise Value Revenue
69.0534
Revenue
920.6 K
Earnings Share
(0.02)
There are over one hundred nineteen available fundamental trend indicators for Theralase Technologies, which can be analyzed over time and compared to other ratios. All traders should should double-check Theralase Technologies' current fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 23.4 M in 2025. Enterprise Value is likely to drop to about 21.8 M in 2025

Theralase Technologies Total Revenue

1.54 Million

Check Theralase Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theralase Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 345.5 K, Interest Expense of 36.7 K or Other Operating Expenses of 4.2 M, as well as many indicators such as Price To Sales Ratio of 40.42, Dividend Yield of 0.0 or PTB Ratio of 13.26. Theralase financial statements analysis is a perfect complement when working with Theralase Technologies Valuation or Volatility modules.
  
This module can also supplement various Theralase Technologies Technical models . Check out the analysis of Theralase Technologies Correlation against competitors.

Theralase Technologies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.4 M3.8 M4.8 M
Slightly volatile
Total Current Liabilities801.6 K1.2 M984 K
Pretty Stable
Property Plant And Equipment Net1 M986.6 K638.3 K
Slightly volatile
Accounts Payable458.3 K784.3 K511.6 K
Slightly volatile
Cash48 K50.5 K2.4 M
Pretty Stable
Non Current Assets Total1.3 M2 M891.8 K
Slightly volatile
Cash And Short Term Investments48 K50.5 K2.4 M
Pretty Stable
Common Stock Shares Outstanding265.6 M253 M136.7 M
Slightly volatile
Liabilities And Stockholders Equity4.4 M3.8 M4.8 M
Slightly volatile
Other Stockholder Equity7.8 M14.4 M7.7 M
Slightly volatile
Total Liabilities859 K1.6 M1.1 M
Slightly volatile
Total Current Assets3.1 M1.7 M3.9 M
Pretty Stable
Accumulated Other Comprehensive Income3.9 M7.2 M3.7 M
Slightly volatile
Short and Long Term Debt Total467.2 K444.9 K181.3 K
Slightly volatile
Other Current Liabilities286.4 K347.9 K352.9 K
Pretty Stable
Net Receivables624.7 K688.4 K654.6 K
Very volatile
Inventory500.9 K756.9 K583.1 K
Slightly volatile
Other Current Assets129.9 K228 K155.8 K
Pretty Stable
Short Term Debt65.3 K107 K133.1 K
Very volatile
Intangible Assets5.6 K5.9 K48.9 K
Slightly volatile
Short Term Investments285.4 K283.1 K316 K
Slightly volatile
Good Will1.5 M1.7 M1.8 M
Slightly volatile
Common Stock29.7 M53.4 M27.6 M
Slightly volatile
Net Tangible Assets5.6 M3.6 M4.3 M
Slightly volatile
Other Assets668.1 K636.2 K202.9 K
Slightly volatile
Short and Long Term Debt22.5 K25.3 K27.6 K
Slightly volatile
Property Plant Equipment775.8 K1.3 M679.5 K
Slightly volatile
Net Invested Capital1.6 M1.7 M3.4 M
Pretty Stable
Net Working Capital360.3 K379.3 K2.4 M
Pretty Stable
Capital Stock44.7 M53.4 M34.6 M
Slightly volatile
Capital Lease Obligations249.3 K444.9 K195.6 K
Slightly volatile
Property Plant And Equipment Gross2.3 M2.4 M2.2 M
Slightly volatile

Theralase Technologies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense36.7 K35 K16.4 K
Pretty Stable
Other Operating Expenses4.2 M6.5 M5.2 M
Slightly volatile
Total Operating Expenses3.6 M5.6 M4.6 M
Slightly volatile
Total Revenue1.5 M1.2 M1.4 M
Pretty Stable
Gross Profit260.9 K274.6 K703.2 K
Slightly volatile
Cost Of Revenue626.3 K879.9 K629.2 K
Slightly volatile
Selling General Administrative1.9 M2.3 M1.9 M
Slightly volatile
Selling And Marketing Expenses83.1 K87.5 K599.7 K
Slightly volatile
Research Development2.2 M3.2 M2.3 M
Slightly volatile
Net Interest Income27.7 K22.3 K21.4 K
Pretty Stable
Interest Income38.7 K57.3 K29.3 K
Slightly volatile
Reconciled Depreciation295.4 K329 K267.6 K
Slightly volatile

Theralase Technologies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2 M1.7 M2.6 M
Slightly volatile
End Period Cash Flow48 K50.5 K2.4 M
Pretty Stable
Depreciation175.5 K329 K183.4 K
Slightly volatile
Stock Based Compensation358.4 K714.4 K374 K
Slightly volatile
Sale Purchase Of Stock2.6 M1.8 M2.3 M
Very volatile
Change To Netincome441.1 K277.2 K335.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio40.4242.54249
Slightly volatile
Days Sales Outstanding210235238
Slightly volatile
Average Payables302.6 K454.5 K416.3 K
Pretty Stable
Stock Based Compensation To Revenue0.550.520.3096
Slightly volatile
Capex To Depreciation0.140.152.9487
Slightly volatile
EV To Sales40.7742.91244
Slightly volatile
Inventory Turnover1.710.891.2159
Pretty Stable
Days Of Inventory On Hand415544477
Pretty Stable
Payables Turnover1.460.861.211
Pretty Stable
Sales General And Administrative To Revenue1.01.711.3558
Slightly volatile
Average Inventory323.4 K473.3 K527.8 K
Pretty Stable
Research And Ddevelopement To Revenue1.292.511.8259
Slightly volatile
Capex To Revenue0.0380.040.2146
Slightly volatile
Cash Per Share2.0E-42.0E-40.0191
Very volatile
Days Payables Outstanding397563423
Slightly volatile
Income Quality1.111.020.853
Slightly volatile
Intangibles To Total Assets5.0E-45.0E-40.0276
Slightly volatile
Current Ratio1.521.65.1266
Slightly volatile
Receivables Turnover3.472.062.6818
Pretty Stable
Graham Number0.10.05730.133
Very volatile
Capex Per Share2.0E-42.0E-40.0015
Slightly volatile
Average Receivables360.5 K235.3 K529.7 K
Pretty Stable
Revenue Per Share0.00530.00560.0151
Slightly volatile
Interest Debt Per Share0.00120.00228.0E-4
Slightly volatile
Debt To Assets0.140.11810.0495
Slightly volatile
Operating Cycle624778715
Slightly volatile
Days Of Payables Outstanding397563423
Slightly volatile
Quick Ratio0.850.94.4865
Slightly volatile
Cash Ratio0.04450.04693.5583
Slightly volatile
Days Of Inventory Outstanding415544477
Pretty Stable
Days Of Sales Outstanding210235238
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.161.0933
Very volatile
Fixed Asset Turnover1.361.434.169
Slightly volatile
Debt Ratio0.140.11810.0495
Slightly volatile
Price Sales Ratio40.4242.54249
Slightly volatile
Asset Turnover0.510.380.4644
Slightly volatile
Gross Profit Margin0.650.60.5387
Pretty Stable

Theralase Technologies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap23.4 M35.6 M35.5 M
Slightly volatile
Enterprise Value21.8 M35.9 M33.1 M
Slightly volatile

Theralase Fundamental Market Drivers

Cash And Short Term Investments43.9 K

About Theralase Technologies Financial Statements

Theralase Technologies investors use historical fundamental indicators, such as Theralase Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theralase Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.5 M
Total Revenue1.2 M1.5 M
Cost Of Revenue879.9 K626.3 K
Stock Based Compensation To Revenue 0.52  0.55 
Sales General And Administrative To Revenue 1.71  1.00 
Research And Ddevelopement To Revenue 2.51  1.29 
Capex To Revenue 0.04  0.04 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(4.94)(4.69)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Theralase Stock Analysis

When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY